Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Boehlen – page 59

1 042 clinical trials in Boehlen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Boehlen at a glance
1 042
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 042 trials in Boehlen

Open in trial search

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Hepatic cirrhosis

Not recruiting

Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Angelman's syndrome

Not recruiting

Study on the Long-Term Safety of GTX-102 for Patients with Angelman Syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Apazunersen
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study of Atezolizumab and Tiragolumab for Patients with Unresectable Esophageal Squamous Cell Carcinoma After Chemoradiotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on Zolbetuximab and mFOLFOX6 for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Study on the Effectiveness and Safety of Reparixin for Adults with Acute Respiratory Distress Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Reparixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Aortic stenosis

Not recruiting

Study of spironolactone and Dihydralazine for reducing heart muscle scarring in patients with severe aortic valve narrowing after valve replacement procedure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Spironolactone
  • Sponsor:Universitaetsmedizin Goettingen

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Boehlen

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on Irritable Bowel Syndrome (IBS), specifically targeting the diarrhea-predominant form. The research evaluates an innovative bacterial treatment approach using E. coli DSM 17252 to improve digestive health outcomes.

  • Symptom Management
  • Microbiome-Based Therapy
  • Gastrointestinal Disorders

This trial aims to advance treatment options for patients dealing with chronic digestive symptoms.

02 Immunology Studies

Groundbreaking research into IgG4-Related Disease, evaluating the effectiveness of obexelimab administered subcutaneously. The study focuses on preventing disease flares following glucocorticoid therapy.

  • Autoimmune Conditions
  • Disease Management
  • Novel Therapeutic Approaches

This research represents a significant step forward in developing targeted treatments for rare immunological disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.